

HTANGEL

Keeping you up-to-date on
HTA decisions

Issue 39: July 2026

Cancer approvals dominate July as retifanlimab gets mixed verdicts across markets.

This newsletter summarises final decisions from NICE, SMC, HAS & IQWiG from published reports in July 2026.

Good news

Fezolinetant, approved for moderate to severe vasomotor symptoms of menopause in Scotland; **Nerandomilast**, approved for both progressive and idiopathic pulmonary fibrosis in France; and **Pembrolizumab**, approved for cervical cancer in England, squamous cell carcinoma of the head and neck in France and muscle-invasive bladder cancer in France.

Mixed news

Retifanlimab, approved for Merkel cell carcinoma and anal cancer in Germany but not approved for anal cancer in France.

Bad news

Avapritinib not approved for systemic mastocytosis or mast cell leukaemia in Scotland; **Depemokimab**, not approved for chronic rhinosinusitis with nasal polyps in Germany; and **Netarsudil**, not approved for open-angle glaucoma in England.

Approvals

22

Non-approvals

8

HTANGEL


Issue 39: July 2026

Pharmacological Technologies



France
HAS AP588

Cancer
Acute lymphoblastic
leukaemia
BLINATUMOMAB




Germany
IQWiG G26-05

Cancer
Biliary tract cancer
ZANIDATAMAB



France
HAS AP592

Cancer
Anal cancer
RETIFANLIMAB



Scotland
SMC2880

Cancer
Bladder cancer
DURVALUMAB



Germany
IQWiG G26-08

Cancer
Anal cancer
RETIFANLIMAB



France
HAS AP586

Cancer
Bladder cancer
PEMBROLIZUMAB WITH
ENFORTUMAB VEDOTIN



Scotland
SMC2846

Cancer
B-cell lymphoma
GLOFITAMAB



France
HAS AP576

Cancer
Breast cancer
PALBOCICLIB



HTANGEL

Issue 39: July 2026

Pharmacological Technologies



England
NICE TA1174

Cancer
Cervical cancer
CEMPIPLIMAB



France
HAS AP585

Cancer
Head and neck
cancer
PEMBROLIZUMAB



England
NICE TA1177

Cancer
Cervical cancer
PEMBROLIZUMAB



Scotland
SMC2849

Cancer
Leukaemia
AVAPRITINIB



England
NICE TA1173

Cancer
Chronic lymphocytic
leukaemia
PIRTOBRUTINIB



Scotland
SMC2910

Cancer
Malignant melanoma
TEBENTAFUSP



France
HAS AP583

Cancer
Glioma
TOVORAFENIB



Germany
IQWiG G26-07

Cancer
Merkel cell
carcinoma
RETIFANLIMAB



HTANGEL

Issue 39: July 2026

Pharmacological Technologies



Germany
IQWiG A26-39, A26-38

Cancer
Multiple myeloma
BELANTAMAB
MAFODOTIN



Scotland
SMC2898

Endocrine
Menopause
FEZOLINETANT



Germany
IQWiG A26-31

Cancer
Prostate cancer
NIRAPARIB WITH
ABIRATERONE



England
NICE TA1176

Endocrine
Type 1 diabetes
mellitus
TEPLIZUMAB



England
NICE TA1181

Cardiovascular
Hypertrophic obstructive
cardiomyopathy
AFICAMTEN



England
NICE TA1180

Eye
Glaucoma
NETARSUDIL



Germany
IQWiG A26-34, A26-35

Endocrine
Menopause
ELINZANETANT



France
HAS AP595

Genetic & Metabolic
Metachromatic
leukodystrophy
ATIDARSAGENE
AUTOTEMCEL



HTANGEL

Issue 39: July 2026

Pharmacological Technologies



France
HAS AP544

Respiratory
Idiopathic pulmonary
fibrosis
NERANDOMILAST



England
NICE TA1175

Skin
Hyperhidrosis
GLYCOPYRRONIUM
BROMIDE



France
HAS AP543

Respiratory
Progressive
pulmonary fibrosis
NERANDOMILAST



Scotland
SMC2870

Other
Eosinophilic granulomatosis
with polyangiitis
BENRALIZUMAB



Germany
IQWiG A26-37, A26-
36

Respiratory
Rhinosinusitis
DEPEMOKIMAB



England
NICE TA1178

Skin
Alopecia areata
DEURUXOLITINIB




HTANGEL

Issue 39: July 2026

Further Information

HTAngel is designed to help keep you up to date with the latest HTA decisions from NICE, SMC, HAS & IQWiG.

Below is a breakdown of the tiles in the newsletter.



At Crystallise we aim to provide an innovative approach to processing information, using software tools to automate processes that are slower and less accurate when done by humans. Our approach provides clients with greater transparency and scope than they could find for the same budget elsewhere. We work with a network of experts and organisations that help us support clients efficiently and effectively, and are proud of our flexible and ingenious way of solving their problems.

For further information about HTAngel contact
newsletter@crystallise.com

To speak to us about our services contact
contact@crystallise.com

